NEWTOWN, PA – Forian Inc. announced that it has completed the mixture of Helix Technologies, Inc. (OTCQB:HLIX) and Health-related Outcomes Investigation Analytics, LLC. The mixture empowers Forian to offer a special suite of SaaS options, information management capabilities and proprietary information and analytics to optimize and measure operational, clinical and economic overall performance for buyers inside the classic and emerging life sciences, healthcare payor and provider segments as properly as cannabis producers, dispensaries, cultivators and regulators.
Forian expects to start trading on The Nasdaq Stock Marketplace LLC beneath the symbol “FORA” on March three, 2021. Shares of Helix will no longer trade on the OTCQB starting on March three, 2021 insofar as every share of Helix was exchanged for .05 shares of Forian popular stock in the merger. There are about 32 million shares of Forian popular stock outstanding on a completely diluted basis.
Forian’s proprietary information and integrated information management experience, coupled with its team’s deep background in SaaS-primarily based platforms and industrial and clinical analytics, complement Helix’s business-top seed-to-sale compliance tracking and point of sale technologies for the rapidly evolving and swiftly increasing cannabis business. The integration of Forian’s information management platform and assets additional differentiate Helix’s BioTrack and Cannalytics options by infusing analytics into workflows to assist buyers make informed enterprise choices. Forian will increase present cannabis business requirements in information, analytics and reporting. Information from Helix’s technologies offerings will energy new analytics for Forian healthcare customers interested in actual planet proof pertaining to the security, efficacy, good quality and overall health outcomes related with cannabinoid-primarily based merchandise.
“I want to compliment Zachary Venegas, Scott Ogur and the complete Helix Technologies group for constructing a top technologies options provider to one particular of the biggest client bases in the cannabis business,” commented Dan Barton, Chief Executive Officer of Forian. “As the use of option therapeutics continues to develop at a speedy price, Forian is uniquely positioned to assistance the healthcare and cannabis industries. The capabilities and experience that we now have in our organization, collectively with our commitment to invest, will drive innovations to assistance our customers’ clinical, solution improvement and promoting requires.”
“The addition of Helix meaningfully enhances the worth proposition of the Forian platform, which is a important information driven engine for driving development across our enterprise,” stated Forian Executive Chairman Max Wygod.
Forian’s executive group will be led by Executive Chairman Max Wygod, Chief Executive Officer Dan Barton and Chief Method Officer Adam Dublin. Helix’s Chief Executive Officer Zachary Venegas and Helix’s Chief Economic Officer Scott Ogur will stay engaged in the enterprise in advisory capacities. Leadership of the operations of Forian will be managed by personnel from each the MOR Analytics and Helix teams.
Forian’s and MOR Analytics’ legal advisor is Duane Morris LLP, and Helix’s legal advisor is Nelson Mullins Riley & Scarborough LLP. ROTH Capital Partners, LLC and Donohoe Advisory Associates LLC advised on Nasdaq and other associated matters.
The transfer agent for Forian and this transaction is Broadridge Corporate Issuer Options, Inc. Shareholders with any concerns on this transaction ought to get in touch with Broadridge Client Service at 877-830-4936. A copy of Forian’s SEC filings can be located at http://sec.gov/edgar.